What Cellenkos does

Cellenkos, Inc. is a clinical-stage biotechnology company founded in 2016 and headquartered in Houston, Texas, developing allogeneic, off-the-shelf regulatory T cell (Treg) therapies for rare inflammatory and autoimmune disorders. Its proprietary CRANE® platform — licensed from MD Anderson Cancer Center and developed by founder Dr. Simrit Parmar — enables enrichment and differentiation of naive Tregs from healthy umbilical cord blood, producing disease-specific products that preferentially home to inflamed tissues via CXCR4 markers, retain suppressor function without plasticity risk (no RORγt expression), and exhibit low immunogenicity enabling administration without patient matching. The pipeline comprises four lead programs: CK0801 for bone marrow failure syndromes/aplastic anemia, CK0802 for steroid-refractory GVHD and COVID-19 ARDS, CK0803 for ALS, and CK0804 for myelofibrosis (the latter developed under an exclusive option agreement with Incyte Pharmaceuticals).

The company operates a wholly owned cGMP manufacturing facility (Cellenkos Manufacturing Facility, CMF) in Houston for process development, technology transfer, and scale-up, and uses Cryoport for temperature-controlled cell therapy logistics. Cellenkos is currently pre-revenue, with future revenue expected from one-time therapeutic product sales of approved cell therapies; pricing has not been publicly disclosed. The company was acquired by Global Cord Blood Corporation (NYSE: CO) in April 2022 for approximately $664 million in cash plus 125 million new shares, and now operates as a wholly owned subsidiary, with the Incyte collaboration carve-out retained separately. Clinical development is supported by alliances with MD Anderson, Johns Hopkins, Mount Sinai, the Michael E. DeBakey VA Medical Center, the University of Texas Health Science Center at Houston, and (from May 2025) King Faisal Specialist Hospital & Research Centre in Saudi Arabia.

Name

Cellenkos

Legal name

Cellenkos, Inc

Website

https://cellenkosinc.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellenkos is a clinical-stage Houston-based biotech developing allogeneic, cord blood-derived regulatory T cell (Treg) therapies using its proprietary CRANE® platform to treat rare inflammatory and autoimmune disorders including aplastic anemia, GVHD, ALS, and myelofibrosis.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Allogeneic cell therapy
• Regulatory T cells
• Cord blood therapy
• Autoimmune disease therapeutics
• Cell therapy platform

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Treg Cell Therapy Commercialization: Pre-revenue clinical stage biotech company. Future revenue expected from commercialization of allogeneic Treg cell therapy products (CK0801, CK0802, CK0803, CK0804) for treatment of autoimmune and inflammatory disorders. Revenue model will be based on one-time therapeutic product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Cellenkos is a clinical-stage biotechnology company developing allogeneic, off-the-shelf, umbilical cord blood-derived regulatory T cell (Treg) therapies for the treatment of autoimmune and inflammatory disorders. Its lead product candidates include CK0801 (bone marrow failure/aplastic anemia), CK0802 (COVID-19 ARDS, GVHD), CK0803 (ALS), and CK0804 (myelofibrosis), all manufactured using the proprietary CRANE platform technology.

Product overview

Cellenkos is a clinical-stage biotechnology company developing a portfolio of allogeneic, off-the-shelf T-regulatory (Treg) cell therapies manufactured using its proprietary CRANE platform technology. The core products include CK0801 (bone marrow failure/aplastic anemia), CK0802 (COVID-19 ARDS), CK0803 (ALS), and CK0804 (myelofibrosis). All products are derived from healthy umbilical cord blood and are designed to suppress inflammation and restore immune homeostasis across autoimmune and inflammatory disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• CK0801
• CK0802
• CK0803
• CK0804
• CRANE® Platform

Quantifiable outcome

• 89.7% probability of beneficial effect for CK0802 in COVID-19 ARDS patients
• +5 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• MD Anderson Cancer CentercoreTechnology or IntegrationLicensing partner for umbilical cord blood T-Regulatory cell therapy platform. Cellenkos was founded in 2016 with the licensing of proprietary Treg cell therapy platform from MD Anderson. Ongoing research collaboration supports the T-REG Program targeting various diseases including ALS, Alzheimer's, MS, IBD, GVHD, aplastic anemia, SLE, RA, and Type 1 diabetes.
• Incyte PharmaceuticalscoreStrategic or Co-development PartnerDecember 2020 development collaboration to investigate combination of ruxolitinib (Jakafi®) and CK0804 in patients with myelofibrosis. Incyte has exclusive option to acquire sole rights to develop and commercialize CK0804 and genetically-modified variants in benign and malignant hematology indications.
• King Faisal Specialist Hospital & Research CentremajorStrategic or Co-development PartnerStrategic MOU signed May 2025 following Saudi-U.S. Investment Forum to advance T regulatory cell therapies for rare diseases. First clinical trial alliance between Saudi Arabia and US. Will launch trials for GVHD and Aplastic Anemia. Cellenkos will assist KFSHRC in building local cell and gene therapy manufacturing infrastructure, training, and education, with expansion into neurodegenerative and cardiovascular disorders.
• Icahn School of Medicine at Mount SinaimajorStrategic or Co-development PartnerApril 2024 sponsored research agreement to explore application of CK0804 CXCR4 enriched allogeneic cord blood T regulatory cells for treatment of myelofibrosis under guidance of Dr. Ronald Hoffman, Director of Myeloproliferative Disorders Research Program.
• The University of Texas Health Science Center at HoustonminorStrategic or Co-development PartnerJune 2018 research collaboration for application of cord blood-derived regulatory T cells (CK0801) as adoptive therapy for neuroinflammatory disorders, first studying Guillain-Barré Syndrome.
• Johns Hopkins University HospitalminorStrategic or Co-development PartnerPhysician-investigators at Johns Hopkins reported promising clinical data in July 2020 on treatment of COVID-19 induced ARDS with Cellenkos' cord blood-derived Treg cell therapy, published in Annals of Internal Medicine.
• Michael E. DeBakey VA Medical CenterminorStrategic or Co-development PartnerJanuary 2024 announcement of new clinical trial using CK0803 off-the-shelf allogeneic Treg cells modified to target neuroinflammation for treatment of Amyotrophic Lateral Sclerosis (ALS).

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Century Therapeutics: Clinical-stage biotech developing allogeneic iPSC-derived immune cell therapies including CAR-T and Treg programs for cancer and autoimmune diseases. Comparable allogeneic platform ambition with focus on off-the-shelf cell therapy scalability and engineered immune cell approaches.
• Kyverna Therapeutics: Clinical-stage biotech developing allogeneic and autologous CAR-Treg cell therapies for autoimmune diseases including lupus nephritis, multiple sclerosis, and inflammatory bowel disease. Most directly comparable Treg cell therapy competitor with similar disease-specific tissue-targeting strategy.
• Sonoma Biotherapeutics: Clinical-stage biotech developing engineered Treg cell therapies for autoimmune and inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and type 1 diabetes. Competes directly in the autoimmune Treg cell therapy space with similar allogeneic platform ambitions.
• Atara Biotherapeutics: Clinical-stage allogeneic T-cell therapy company with programs including EBV-specific Tregs (ATA3219) for autoimmune diseases. Comparable allogeneic, off-the-shelf T-cell platform with overlapping indication strategy and similar manufacturing/scale-up challenges.
• Coya Therapeutics: Clinical-stage biotech developing Treg-focused therapeutics for neurodegenerative and inflammatory diseases including ALS, Alzheimer's, and frontotemporal dementia. Direct overlap with Cellenkos's CK0803 ALS program and shared focus on neuroinflammation mechanism.
• Quell Therapeutics: Clinical-stage biotech developing engineered allogeneic Treg cell therapies for autoimmune and inflammatory diseases with primary focus on liver transplant tolerance, inflammatory bowel disease, and multiple sclerosis. Direct competitor using modified Treg approaches for immune-mediated conditions.

Broad incumbents

• Bristol Myers Squibb: Large pharma with established CAR-T franchise (Breyanzi, Abecma) and growing investment in autoimmune cell therapy programs including Tregs. Broad incumbent with cell therapy manufacturing infrastructure and commercial channels that could compete with or acquire Cellenkos-style assets.
• Pluristem Therapeutics: Cell therapy company developing placenta-derived cell therapies (PLX cells) for inflammatory conditions including critical limb ischemia and acute radiation syndrome. Broader incumbent in the cell therapy space with overlapping regenerative/immunomodulatory mechanism for inflammatory disorders.
• Vertex Pharmaceuticals: Large biotech with cell therapy programs (VX-880/860 for type 1 diabetes) and emerging autoimmune cell therapy strategy. Broad incumbent with capital, manufacturing scale, and commercial reach in cell-based therapeutics including potential Treg programs.

Emerging players

• Tr1X Therapeutics: Early-stage biotech developing allogeneic Tr1 (Type 1 regulatory T) cell therapies for autoimmune and inflammatory diseases. Emerging competitor with overlapping mechanism (regulatory T cell-based immune modulation) and similar allogeneic platform approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellenkos